NCT03043001

Memantine in Bipolar Patients With Alcoholism

Using Memantine in Treating Bipolar Disorder Comorbid With Alcoholism

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: National Cheng-Kung University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Since memantine may not only inhibit overactivity of microglial cell, but also repair the damaged neurons and neurogenesis through activation of astroglial cell and release of neurotrophic factors, the investigators propose that the neurotrophic effect of memantine may benefit neurodegenerative diseases including bipolar disorders (BP) and alcohol dependence. In the current study, the investigator will investigate whether add-on memantine at a dose of 5 mg/day has a beneficial effect on BP comorbid with alcohol dependence.

Detailed description

Each individual enter into this project will receive regulate treatment adding-on memantine medication. During each visit, patients will receive evaluation for their symptoms and plasma Brain-Derived Neurotropic Factor (BDNF), cytokines (e.g.., Interleukin-6(IL-6), IL-8) and neuropsychological performance.

Conditions

• AOD Effects and Consequences

Interventions

Type	Name	Description
DRUG	Memantine	All the subjects will receive add-on memantine for 12 week

Timeline

• Start date: 2014-01-01
• Primary completion: 2016-12-31
• Completion: 2017-12-31
• First posted: 2017-02-03
• Last updated: 2017-10-03

Locations

1 site across 1 country: Taiwan